Camp4 Therapeutics Corp
Company Stats
- Market Cap
- $253.5M
- as of Sep 30, 2026
- Shares Outstanding
- 62.8M
- Free Float
- 70.2%
Income Statement
- Revenue
- $3.5M
- Operating Income
- -$52.6M
- Net Income
- -$80.4M
- EBITDA
- -$50.9M
- Non-cash Impairment
- $500,000
- FCF Margin, 3Y Avg
- -6906.0%
- FCF Margin, Worst Year
- -12809.4%
Cash Flow
- Free Cash Flow
- -$29.8M
- FCF Yield
- -11.8%
- Owner FCF Yield
- -13.3%
Balance Sheet
- Cash & Equivalents
- $109.5M
Returns & Capital
- SBC, 3Y Avg
- $3.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.5M | -$29.8M | -852.8% |
| FY2024 | $652,000 | -$46.0M | -7055.7% |
| FY2023 | $350,000 | -$44.8M | -12809.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Insiders Buy Into Boston Scientific Restructuring